Torii Pharmaceutical Co (4551.T) Stock Price
Torii Pharmaceutical Co Price
Over the last 19 years Torii Pharmaceutical Co grew revenue by 2.1% annually, reaching 60.43 B JPY. Earnings per share have grown at 1.0% per year over the last 19 years. For Torii Pharmaceutical Co, the net margin of 8.3% is broadly stable versus 8.4% a few years ago. At today's price the dividend yield works out to roughly 0.00%. The payout ratio is around 67% of earnings. The dividend has grown at 6.1% per year over the past 19 years.
Torii Pharmaceutical Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Torii Pharmaceutical Co business model & stock analysis
Frequently asked questions about Torii Pharmaceutical Co
The business model of Torii Pharmaceutical Co Ltd revolves around the development, manufacturing, and sales of various pharmaceutical products. As a leading pharmaceutical company, Torii Pharmaceutical focuses on research and development to create innovative healthcare solutions. With a wide range of products spanning different therapeutic areas such as cardiovascular, respiratory, and central nervous system disorders, Torii Pharmaceutical aims to improve patient outcomes and enhance quality of life. Through strategic partnerships and collaborations, the company strives to expand its presence in both domestic and international markets, ensuring the delivery of high-quality and effective medications to patients worldwide.
Torii Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.
The main competitors of Torii Pharmaceutical Co Ltd in the market include companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co., Ltd., and Shionogi & Co., Ltd.
Torii Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1921, Torii Pharmaceutical has been providing innovative healthcare solutions for nearly a century. The company specializes in developing and manufacturing high-quality prescription drugs, over-the-counter medications, and healthcare products. With a strong emphasis on research and development, Torii Pharmaceutical has earned a reputation for its commitment to improving global health. Through strategic partnerships and collaborations, the company has expanded its global presence, delivering its products to diverse markets. Torii Pharmaceutical continues to strive for excellence, ensuring the well-being of individuals worldwide through cutting-edge pharmaceutical advancements.
Since its establishment, Torii Pharmaceutical Co Ltd has reached several significant milestones. Notably, the company successfully launched its flagship product, Toubeauty®, an innovative skincare solution beloved by consumers worldwide. Torii Pharmaceutical Co Ltd also expanded its global presence by securing distribution agreements in key markets, further contributing to its growth and success. Additionally, the company has made strides in research and development, leading to the launch of groundbreaking pharmaceutical products that have positively impacted patients' lives. Overall, Torii Pharmaceutical Co Ltd continues to demonstrate its commitment to innovation, excellence, and improving the well-being of individuals through its remarkable achievements.
Torii Pharmaceutical Co Ltd is primarily present in Japan.
Torii Pharmaceutical Co Ltd represents values of excellence, integrity, and innovation. The company believes in delivering high-quality pharmaceutical products that improve the health and well-being of individuals. With a focus on research and development, Torii Pharmaceutical Co Ltd strives to provide innovative solutions and meet the changing needs of patients. The company's corporate philosophy emphasizes the importance of contributing to society through the development of safe and effective medications. By prioritizing patient-centric care, Torii Pharmaceutical Co Ltd aims to become a trusted partner in the global healthcare industry.
6 analysts currently rate the Torii Pharmaceutical Co stock: 4 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Torii Pharmaceutical Co to generate revenue of 66.90 B JPY and earnings per share of 109.20 JPY.
Converted at the current exchange rate, the Torii Pharmaceutical Co share trades at 134.15 T EUR (23.53 TT JPY).
The Torii Pharmaceutical Co share (4551.T) is listed on 2 stock exchanges, including: Tokio (JPX) (4551.T).
Torii Pharmaceutical Co Ltd is a Japanese company specializing in the research, development, production, and marketing of pharmaceuticals. The company was founded in 1921 and is headquartered in Tokyo. The business model of Torii is based on developing and marketing innovative and effective drugs that contribute to improving the lives of patients. The company has a wide range of products in various therapy areas, such as cancer, cardiovascular diseases, metabolic disorders, immunology, and the nervous system. Torii operates in three main business areas: 1. Research and Development: Torii has an extensive research and development pipeline focused on novel drugs. The company invests heavily in the discovery and development of new pharmaceutical compounds and is constantly looking for promising technologies and therapies. 2. Manufacturing and Distribution: Torii has modern production facilities that meet the latest international standards to ensure that products are of high quality and safe. In addition, the company has an extensive distribution network in Japan and internationally to ensure that products can be delivered quickly and effectively to customers. 3. Brand Management: Torii markets and distributes its products under various brand names and is committed to raising awareness among the public and healthcare professionals. The company works closely with medical communities to maximize the effectiveness of its products and achieve broad market acceptance. Some of Torii's key products include: - Trelstar: A drug for the treatment of prostate cancer and endometriosis. - Edaravone: A neuroprotective drug for the treatment of amyotrophic lateral sclerosis (ALS). - Remitch: A drug for the treatment of sleep disorders. - Coniel: A drug for the treatment of hypertension. Torii also pursues a strategy of collaborating with other pharmaceutical companies to accelerate the development of new drugs and expand its global market presence. The company has already successfully formed partnerships with major international pharmaceutical companies such as Sanofi and Pfizer. Overall, Torii's business model aims to be a leading provider of pharmaceuticals that maintains a competitive position in the market through innovative technology, excellent product quality, and strong partnerships with other companies.
The expected revenue of Torii Pharmaceutical Co is 66.90 B JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Torii Pharmaceutical Co is 3.07 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Torii Pharmaceutical Co is currently 215.46 T. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Torii Pharmaceutical Co stock.
The price-to-sales ratio (P/S) of Torii Pharmaceutical Co is currently 9.89 T. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Torii Pharmaceutical Co stock.
The Eulerpool Quality Score for Torii Pharmaceutical Co is 6/10.
The ISIN of Torii Pharmaceutical Co is JP3635800000. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Torii Pharmaceutical Co is 887536. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Torii Pharmaceutical Co is 4551.T. The ticker symbol is used to trade Torii Pharmaceutical Co shares on the stock exchange.
Torii Pharmaceutical Co stock
Torii Pharmaceutical Co Peer Group
Torii Pharmaceutical Co Ticker
Torii Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of Torii Pharmaceutical Co
Our stock analysis for Torii Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.